Free to use COVID-19 Protein Portal launched for researchers in UK
The COVID-19 Protein Portal, established by UKRI and Wellcome, will allow scientists in the UK to access protein reagents needed for research.
List view / Grid view
The COVID-19 Protein Portal, established by UKRI and Wellcome, will allow scientists in the UK to access protein reagents needed for research.
Russian researchers have created a process for the development of mouse models for use in pre-clinical studies of COVID-19 treatments and vaccines.
A new kind of dendritic cell has been discovered by researchers and could play a role presenting antigens to other immune cells during respiratory virus infections.
Researchers have found that molecules from ticks called Evasins have the potential to halt cytokine storms, the leading cause of COVID-19 fatalities.
Bioassays and thin-layer chromatography has been used by scientists to analyse molecules in plant extracts as a fast and cost-effective method for identifying new drug compounds.
A MERS vaccine, which uses RNA-based adjuvants, has demonstrated efficacy in non-human primates and is now being developed as a prophylactic for COVID-19.
A new compound named L1 has demonstrated success in mice, by reducing neuroinflammation and decreasing the levels of amyloid plaques, showing potential as an Alzheimer's treatment.
Tested on plaque reducing assays, researchers have identified a lead candidate multivalent carbohydrate-binding module for the treatment of COVID-19.
Researchers have identified a structural loop in the SARS-CoV-2 S protein and a sequence of four amino acids that they say could help explain its high transmission rate.
Tests have shown that LAL assays produced from L. polyphemus in aquaculture often has a higher activity than lyophilised and preserved LAL from commercial kits.
After analysing the genomic diversity in SARS-CoV-2 by screening over 7,500 viruses from infected patients, researchers have offered clues for COVID-19 drug development.
A molecule called microRNA-744, which influences inflammation, has been revealed by researchers as a new drug target for Sjögren's Syndrome.
Researchers have shown that the activation sequence the SARS-CoV-2 S protein is cleaved by the cellular enzyme furin which is also required for the infection of lung cells.
A rise in biotechnology R&D activities is expected to drive the growth of the immuno-oncology assay market, with a CAGR of 10.6 percent.
An antibody that neutralises both SARS-CoV and SARS-CoV-2 in cell cultures has been discovered by researchers and could be used to treat COVID-19.